Aclaris Therapeutics, Inc. (ACRS) Upgraded to “Buy” by Zacks Investment Research

Zacks Investment Research upgraded shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) from a hold rating to a buy rating in a research note published on Tuesday. The brokerage currently has $31.00 target price on the biotechnology company’s stock.

According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. “

Other equities research analysts have also recently issued reports about the stock. Cantor Fitzgerald reiterated a buy rating and issued a $50.00 price target on shares of Aclaris Therapeutics in a research report on Monday, September 18th. Jefferies Group LLC reiterated a buy rating and issued a $36.00 price target on shares of Aclaris Therapeutics in a research report on Monday, July 31st. BidaskClub raised Aclaris Therapeutics from a hold rating to a buy rating in a research note on Monday, July 24th. Guggenheim reissued a buy rating and issued a $40.00 price target on shares of Aclaris Therapeutics in a research note on Tuesday, July 4th. Finally, ValuEngine raised Aclaris Therapeutics from a sell rating to a hold rating in a research note on Thursday, June 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average price target of $39.20.

Shares of Aclaris Therapeutics (NASDAQ:ACRS) opened at 27.03 on Tuesday. The firm’s market capitalization is $722.67 million. The company has a 50-day moving average of $26.07 and a 200-day moving average of $27.12. Aclaris Therapeutics has a 52 week low of $20.15 and a 52 week high of $33.25.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.12. On average, equities analysts forecast that Aclaris Therapeutics will post ($3.10) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://ledgergazette.com/2017/10/11/aclaris-therapeutics-inc-acrs-upgraded-to-buy-by-zacks-investment-research.html.

In related news, Director Andrew N. Schiff purchased 108,601 shares of the company’s stock in a transaction that occurred on Wednesday, August 16th. The shares were purchased at an average price of $23.02 per share, with a total value of $2,499,995.02. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 16.30% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Ardsley Advisory Partners purchased a new position in Aclaris Therapeutics in the 2nd quarter worth about $407,000. California State Teachers Retirement System increased its stake in Aclaris Therapeutics by 60.8% in the 2nd quarter. California State Teachers Retirement System now owns 35,696 shares of the biotechnology company’s stock worth $968,000 after purchasing an additional 13,500 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in Aclaris Therapeutics by 69.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,831 shares of the biotechnology company’s stock valued at $429,000 after acquiring an additional 6,502 shares in the last quarter. Redmile Group LLC grew its stake in Aclaris Therapeutics by 4.3% during the 2nd quarter. Redmile Group LLC now owns 94,560 shares of the biotechnology company’s stock valued at $2,564,000 after acquiring an additional 3,860 shares in the last quarter. Finally, State Street Corp grew its stake in Aclaris Therapeutics by 67.1% during the 2nd quarter. State Street Corp now owns 330,755 shares of the biotechnology company’s stock valued at $8,971,000 after acquiring an additional 132,866 shares in the last quarter. 95.85% of the stock is currently owned by hedge funds and other institutional investors.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Comp

According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. “

Other equities research analysts have also recently issued reports about the stock. Cantor Fitzgerald reiterated a buy rating and issued a $50.00 price target on shares of Aclaris Therapeutics in a research report on Monday, September 18th. Jefferies Group LLC reiterated a buy rating and issued a $36.00 price target on shares of Aclaris Therapeutics in a research report on Monday, July 31st. BidaskClub raised Aclaris Therapeutics from a hold rating to a buy rating in a research note on Monday, July 24th. Guggenheim reissued a buy rating and issued a $40.00 price target on shares of Aclaris Therapeutics in a research note on Tuesday, July 4th. Finally, ValuEngine raised Aclaris Therapeutics from a sell rating to a hold rating in a research note on Thursday, June 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average price target of $39.20.

Shares of Aclaris Therapeutics (NASDAQ:ACRS) opened at 27.03 on Tuesday. The firm’s market capitalization is $722.67 million. The company has a 50-day moving average of $26.07 and a 200-day moving average of $27.12. Aclaris Therapeutics has a 52 week low of $20.15 and a 52 week high of $33.25.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.12. On average, equities analysts forecast that Aclaris Therapeutics will post ($3.10) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://ledgergazette.com/2017/10/11/aclaris-therapeutics-inc-acrs-upgraded-to-buy-by-zacks-investment-research.html.

In related news, Director Andrew N. Schiff purchased 108,601 shares of the company’s stock in a transaction that occurred on Wednesday, August 16th. The shares were purchased at an average price of $23.02 per share, with a total value of $2,499,995.02. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 16.30% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Ardsley Advisory Partners purchased a new position in Aclaris Therapeutics in the 2nd quarter worth about $407,000. California State Teachers Retirement System increased its stake in Aclaris Therapeutics by 60.8% in the 2nd quarter. California State Teachers Retirement System now owns 35,696 shares of the biotechnology company’s stock worth $968,000 after purchasing an additional 13,500 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in Aclaris Therapeutics by 69.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,831 shares of the biotechnology company’s stock valued at $429,000 after acquiring an additional 6,502 shares in the last quarter. Redmile Group LLC grew its stake in Aclaris Therapeutics by 4.3% during the 2nd quarter. Redmile Group LLC now owns 94,560 shares of the biotechnology company’s stock valued at $2,564,000 after acquiring an additional 3,860 shares in the last quarter. Finally, State Street Corp grew its stake in Aclaris Therapeutics by 67.1% during the 2nd quarter. State Street Corp now owns 330,755 shares of the biotechnology company’s stock valued at $8,971,000 after acquiring an additional 132,866 shares in the last quarter. 95.85% of the stock is currently owned by hedge funds and other institutional investors.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Analyst Recommendations for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply